# Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Study · id `cardio:ct-nct01147666` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01147666](<https://clinicaltrials.gov/study/NCT01147666>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01147666

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT01147666. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2012-10-15 (actual). Results posted on 2022-01-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Started: 2010-05-17 (actual) (ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Primary completion: 2012-10-15 (actual) (ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Completion: 2012-10-15 (actual) (ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Results first posted: 2022-01-11 (ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01147666, source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01147666-2022-01-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
- Condition: End Stage Renal Disease
- Condition: Anemia
- Intervention (Drug): Roxadustat
- Intervention (Drug): Epoetin Alfa
- Intervention (Other): Placebo
- Lead sponsor: Kyntra Bio
- Lead sponsor class: INDUSTRY
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Astellas Pharma Inc
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Kyntra Bio (`cardio:org-kyntra-bio`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: f6ba3a5ed85b4ee20d08b3ba078438dfd59d60c6349ebfa1da3b16da5b44d9dd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
